Intrust Bank NA Has $750,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Intrust Bank NA increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,717 shares of the company’s stock after purchasing an additional 281 shares during the quarter. Intrust Bank NA’s holdings in Novo Nordisk A/S were worth $750,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in NVO. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $28,000. Albion Financial Group UT increased its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the last quarter. Sound Income Strategies LLC raised its stake in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $46,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.1 %

NVO opened at $69.36 on Friday. The stock has a fifty day moving average of $82.33 and a 200-day moving average of $98.89. The company has a market capitalization of $311.23 billion, a P/E ratio of 21.08, a P/E/G ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a fifty-two week low of $69.18 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.